| 摘要 |
FIELD: medicine, pharmaceutics.SUBSTANCE: inventions concern the influenza virus strains A/PR/8/59/M2 (H1N1), A/California/1/66 (H2N2) and A/Tokyo/3/67 (H2N2). The vaccinal strains A/59/M2/California/66/2211 (H2N2) and A/59/M2/Tokyo/67/22111 (H2N2) are reassortants prepared by crossing epidemic viruses A/California/1/66 (H2N2) and A/Tokyo/3/67 (H2N2) with cold-adapted heat-sensitive virus A/PR/8/59/M2 (H1N1). The strains A/59/M2/California/66/2211 (H2N2) and A/59/M2/Tokyo/67/22111 (H2N2) are characterised by heat sensitivity, cold adaption, safety and immunogenicity for laboratory animals. The reassortants has inherited two genes coding surface virus antigens (hemagglutinin and neuraminidase) from the epidemic virus and the rest six genes coding non-glycated proteins, from the attenuation donor A/PR/8/59/M2 (H1N1).EFFECT: presented inventions can be used in preparing a live influenza intranasal vaccine for adults and children.3 cl, 2 dwg, 4 tbl, 1 ex |
